Kypha Inc., founded in St. Louis, is a medical diagnostics company dedicated to revolutionizing immune system monitoring. Their core mission is to provide precise, real-time immune insights to facilitate earlier and more informed treatment decisions, ultimately improving patient outcomes. Kypha offers an innovative testing platform designed for precision monitoring of immune system activity, targeting both patient care and the advancement of immune-targeted drug development. Their market focus is primarily within the United States.

Notable affiliated individuals and investors include key figures in the medical diagnostics and biotech industries, contributing to Kypha's credibility and growth. The company has achieved significant milestones in developing their diagnostic platform, which has the potential to set a new global standard in immune monitoring. Kypha's impact lies in its ability to transform patient care by enabling comprehensive and frequent assessments of immune activity, thus paving the way for more personalized and effective treatments for immune-related conditions.